First Patient at MD Anderson Cancer Center at Cooper Receives New Targeted Cancer Therapy
A South Jersey man is the first patient at MD Anderson Cancer Center at Cooper to receive Lutathera, an innovative new treatment option for patients with a rare form of cancer.
Lutathera is a targeted radioactive drug approved for the treatment of patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs), a rare category of tumors that can form in the pancreas or other parts of the gastrointestinal tract. Read more.



